Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC). Meeting Abstract

cited authors

  • Steinberg, Gary D.; Shore, Neal D.; Karsh, Lawrence Ivan; Bailen, James L.; Bivalacqua, Trinity; Chamie, Karim; Cochran, James S.; David, Richard; Grubb, Robert L.; Harb, Wael A.; Holzbeierlein, Jeffrey M.; Kamat, Ashish M.; Trabulsi, Edouard John; Walsh, William Vincent; Williams, Michael Brandon; Wolk, Fredrick; Woods, Michael; Price, Melissa Leigh; Early, Brandon; Schreiber, Taylor Houghton

Publication Date

  • May 20, 2017

webpage

published in

category

volume

  • 35